Program
Alpha-1 15%
Its studies are mostly in alpha 1-Antitrypsin Deficiency, led by Grifols.
Furthest: phase 3, since Apr 21, 20262 company-led studies, 1 open or runningNext primary completion: Sep 30, 2027 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Grifols | 21 open or running | phase 3since Apr 21, 2026 | Jan 20, 2021 | Sep 30, 2027phase 3 · NCT07555483 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 20, 2021First study: phase 2 study in alpha 1-Antitrypsin DeficiencyFirst studyNCT04722887 · 17 enrolled · United States
- Apr 21, 2026Phase 3 study in alpha 1-Antitrypsin DeficiencyPhase 3 reachedNCT07555483 · 40 planned · United States, Denmark, Germany and more
Ahead
- Sep 30, 2027Primary completion: phase 3 study in alpha 1-Antitrypsin DeficiencyNCT07555483
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07555483alpha 1-Antitrypsin Deficiency · United States, Denmark, Germany and more | 3 | Recruiting | Sep 30, 2027 | 40 |
| NCT04722887alpha 1-Antitrypsin Deficiency · United States | 2 | Completed | Aug 1, 2025 | 17 |
How it is read
Names in the registry
- “Alpha-1 15%”, 2 entries
Conditions, from the studies’ own filings
- alpha 1-Antitrypsin Deficiency, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.